D.A. Davidson & CO. Sells 4,500 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

D.A. Davidson & CO. lowered its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 3.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 110,900 shares of the company’s stock after selling 4,500 shares during the period. D.A. Davidson & CO.’s holdings in MiMedx Group were worth $1,067,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its stake in shares of MiMedx Group by 8.5% in the 4th quarter. Principal Financial Group Inc. now owns 60,226 shares of the company’s stock valued at $579,000 after acquiring an additional 4,731 shares during the last quarter. Palumbo Wealth Management LLC acquired a new position in MiMedx Group during the fourth quarter valued at approximately $171,000. Van ECK Associates Corp bought a new stake in MiMedx Group in the fourth quarter valued at approximately $40,000. Savant Capital LLC acquired a new stake in MiMedx Group in the fourth quarter worth $100,000. Finally, SG Americas Securities LLC raised its holdings in MiMedx Group by 79.9% in the fourth quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock worth $802,000 after purchasing an additional 37,031 shares during the period. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

NASDAQ MDXG opened at $7.98 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 14.51 and a beta of 1.94. The business has a 50 day simple moving average of $8.84 and a 200 day simple moving average of $7.66. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.